Mangaluru Chalo: Cops scuttle bike rally as BJP defies ban

Jeddah: The first chartered flight for repatriation passengers from Jeddah to Bengaluru organized by Karnataka NRI Forum Jeddah – Saudi Arabia was successfully landed at Bengaluru airport by 01.00 am on 19th July 2020.

Spice Jet (SG9884) departed from King Abdul Aziz International Airport Jeddah by 05.00 pm local time with 177 stranded passengers which includes 12 Pregnant Woman, 3 infants, 44 Short term visa holders, 3 medical emergency patients and 115 migrate workers and labours from various districts of Karnataka state.

Karnataka NRI Forum Jeddah, a registered charitable organization under Government of Karnataka & Indian Consulate Jeddah - Saudi Arabia, helping the Kannadigas overseas & in Karnataka State as well, has initiated major role for helping stranded Kannadigas to travel back to home. During Pandemic hundreds of stranded Kannadigas were approached to the forum and requested to arrange special chartered flight to Bengaluru from Jeddah.

Initiating from collecting the data of passengers, the forum’s special panel including its President Mr. Mohammed Mansoor, Secretary Mr. Peter Mascarenes, Vice Presidents Mr. Nasir Khurshid, Dr.Ashfaque Maniyar, Chief Coordinator Mr. Shaikh Saoud, Cultural Secretaries Mr. Arifulla Shariff and Mr. Rajesh Suvarna, Treasurer Mr. Habib Rahman and Press Secretary Mr. Baig, the forum’s members have worked very hard to conclude this task very successful. 

The forum provided food packets as refreshment, complementary PPE kitsto each passenger as precaution against the spread of any infections while travelling and also guided all passengers by supporting them in Awdha portal (Saudi Passport Department) and Seva Sindhu portal registration of Government of Karnataka.

The official travel partner ITL Travel Management Company has rendered remarkable service to the passengers not only in ticketing but also supported with top priority in confirming the aircraft from SPICE JET and availed good service from ground staff at Jeddah Airport. 

All passengers have reached safely to their homes after completing the 7 days institutional quarantine at Bengaluru. 100% passengers had NEGETIVE report on Covid-19 test made on arrival as well as after institutional quarantine. 

In the press release published from the President, Mr. Mohammed Mansoor has expressed his prodigious gratitude to the Ambassador of India to Saudi Arabia H. E. Dr. Ausaf Sayeed, Deputy Consul General of India - Jeddah Mr. Y Saber and Chief Minister of Karnataka State Shri B. S. Yediyurappafor providing necessary approvals and NOC for the chartered flight operation. He also conveyed his boundless appreciationto Shri B. Y. Raghavendra, Member of Parliament Shimoga District (Karnataka) for his swift support extended to the forum and as well to Dr. Aarathi Krishna, Ex-Deputy Chairperson – NRI Forum of Karnataka – Government of Karnataka for her significant guidance and support on completing this mission.

The forum has thanked all the officers in King Abdul Aziz International Airport Jeddah and Kempegowda International Airport Bengaluru for the facilities provided to the passengers. The Forum has thanked all passengers travelled for their calmness and also thanked to all other members of the forum, Staff of ITL Travels and SPICE JET for their tremendous support extended throughout the mission accomplishment.

If everything goes as Russia’s expectation, it will be world’s first country to approve a coronavirus vaccine for widespread in the second week of August despite safety and efficacy concerns, according to a report. The adenoviral vector-based vaccine developed by Russian military and government researchers is currently in phase 2 trials.

According to a report from CNN, Russian officials are hoping to get approval for the COVID-19 vaccine developed by the Moscow-based Gamaleya Institute on Agust 10 or even before that. The officials told the outlet that the vaccine will be approved for public use with frontline healthcare workers receiving it first.

“It’s a Sputnik moment,” said Kirill Dmitriev, head of Russia’s sovereign wealth fund, which is financing Russian vaccine research, referring to the successful 1957 launch of the world’s first satellite by the Soviet Union, according to CNN.

“Americans were surprised when they heard Sputnik’s beeping. It’s the same with this vaccine. Russia will have got there first,” he was quoted as saying.

However, Russia is yet to release the scientific data on its coronavirus vaccine trials, hence, questions remain about the safety and efficacy of the vaccine, said the report. The vaccine is in the second phase of testing with developers planning to launch the phase 3 trials sometime after August 3.

Earlier, Interfax reported, citing Health Minister Mikhail Murashko, that the vaccine will be widely used in parallel with phase 3 trials. He said the country plans to vaccinate medics who are at high-risk for COVID-19 next month before clinical trials are completed.

Murashko added that individuals at higher risk of getting infected with the coronavirus such as older people or those with health conditions will also be prioritised for the vaccine, although he did not estimate or reveal when that would happen. The minister added 800 people will be recruited for the phase 3 trials.

Meanwhile, health officials were more cautious considering the fact that human testing of the vaccine is incomplete, and the state registration is expected to begin after August 3, reported The Moscow Times.

On Monday, Moderna and Pfizer announced the commencement of the final phase 3 trials of their candidate vaccines against the SARS-CoV-2 virus, which has so far claimed at least 654,477 lives and infected 16,514,500 people worldwide. 

Researchers will recruit up to 30,000 volunteers in separate trials both backed by the US government. India's first indigenous coronavirus vaccine, COVAXIN, is undergoing phase 1 human clinical trials across the country. More than 150 COVID-19 vaccines are being developed all over the world with at least six candidates already in late-stage clinical trials.